Theranostic Biomarkers for Schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Biomarker Research

Background:

• Schizophrenia is a highly heritable, complex neurodevelopmental brain disorder with poorly understood genetic and neurobiological underpinnings.
• Current diagnostic and therapeutic strategies for schizophrenia are limited by the lack of validated, easily accessible biomarkers.
• Existing research focuses on neuroimmune, neuroendocrine, metabolic, neurotransmitter, and neurotrophic factors, but clinical utility remains elusive.

Purpose of the Study:

• To review potential biomarkers for schizophrenia.
• To propose the development and use of accessible, blood-based multi-marker panels for improved patient management.
• To highlight the urgent need for diagnostic, prognostic, and theranostic biomarkers in schizophrenia.

Main Methods:

• This is a review article, synthesizing existing research on schizophrenia biomarkers.
• It discusses various categories of potential biomarkers, including those related to immune processes, metabolic disorders, and neuroendocrine/neurotrophin/neurotransmitter alterations.
• The focus is on proposing a multi-marker panel approach using accessible blood samples.

Main Results:

• No single validated biomarker currently exists for clinical use in schizophrenia.
• Combining multiple markers in panels shows promise for discriminating patient subgroups and identifying underlying pathologies.
• Blood-based panels integrating immune, metabolic, and neurobiological markers are suggested as a viable strategy.

Conclusions:

• The development of comprehensive, blood-based biomarker panels is an unmet need in schizophrenia research.
• Such biomarkers are essential for improving diagnostic accuracy, monitoring treatment response, and enabling personalized medicine approaches.
• Advancing biomarker discovery will enhance patient quality of life and reduce global healthcare costs associated with schizophrenia.